News | September 22, 2014

New Study Examines the Optimal Duration Time of Dual Antiplatelet Therapy in Patients With Second-generation Drug-eluting Stents

Results of SECURITY trial reported at TCT 2014; findings simultaneously published in the Journal of the American College of Cardiology

September 22, 2014 — According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to patients who received DAPT for a full year. Findings were reported Sept. 15 at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Results of the trial were simultaneously published in the Journal of the American College of Cardiology.

The optimal required duration of DAPT in patients implanted with a second-generation DES is a subject of current controversy, with recent studies suggesting that the currently recommended standard of one year of DAPT may be longer than necessary. The SECURITY trial was a randomized, multicenter, multinational, investigator-driven study that aimed to address the need for prolonged use DAPT following the implantation of second-generation DES for patients without high-risk acute coronary syndromes.

SECURITY was designed to test the non-inferiority of six months of DAPT following second generation DES implantation to 12 months of DAPT. Patients with a diagnosis of stable or unstable angina or documented silent ischemia undergoing revascularization with at least one second-generation DES were eligible for the study. A total of 1,399 patients were randomized, 682 assigned to the six-month and 717 to the 12-month group.

After 12 months, the incidence of the primary endpoint (the composite of cardiac death, myocardial infarction (MI), stroke, definite or probable stent thrombosis, or bleeding academic consortium criteria (BARC) type 3 or 5 bleeding) was 4.5 percent in the six-month group compared to 3.7 percent in the 12-month group. After 24 months, both the six-month and 12-month groups showed similar incidences of cardiac death (0.9 percent vs. 0.8 percent, p=0.925), MI (3.1 percent vs. 2.6 percent, p=0.636), stroke (0.9 percent vs. 0.4 percent, p=0.636), stent thrombosis (0.4 percent vs. 0.4 percent, p=0.951) and BARC 3 or 5 bleeding (0.7 percent vs. 1.1 percent, p=0.496).

The rates of the 12-month secondary endpoint (composite of cardiac death, spontaneous MI, stroke, definite or probable stent thrombosis, or BARC type 2, 3 or 5 bleeding at 12 and 24 months) were also similar among the six-month DAPT and 12 month DAPT groups. At 12 months, the incidence of the secondary composite endpoint was 5.3 percent in the six-month group compared to 4 percent in the 12-month group. In the year that followed, both groups had lower incidences of secondary composite endpoints (1.5 percent and 2.2 percent, respectively).

A multivariable analysis found that patient age of 75 years or older, stent type used, mean number of stents implanted, mean stent length, and mean stent size as significant independent predictors of the primary endpoint.

“Six-months of DAPT appeared to be non-inferior to a 12-month regimen in patients undergoing PCI with a second generation DES regarding the primary composite endpoint of cardiac death, MI, stroke, definite or probable stent thrombosis, or BARC type 3 or 5 bleeding at 12 months of clinical follow-up,” said lead investigator Antonio Colombo, M.D. Colombo is the director, Cardiac Catheterization Laboratory of MO GVM Centro Cuore Columbus/San Raffaele Hospital in Milan, Italy.

“Additionally, the six-month DAPT group appeared to be non-inferior to the 12-month group regarding the incidence of the secondary composite endpoints defined by the study protocol,” he said.

The SECURITY trial was funded by grants from Medtronic and Terumo. Colombo reported being a minor shareholder of Direct Flow Inc. 

For more information: www.crf.org and www.tctconference.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init